Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)
ClinicalTrials.gov Identifier: NCT04593927
Novartis Reference Number: CBAF312A1401
Last Update: Dec 23, 2022
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.
Interventions
Eligibility Criteria
Inclusion Criteria:
Patients prescribed Mayzent for prevention of relapses and delay of progression of physical disability in secondary progressive multiple sclerosis
Exclusion Criteria:
-
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]